(Q35711010)

9 August 2017

1 reference

title

Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function (English)

1 reference

9 August 2017

1 reference

Konstadinidou I

1

1 reference

9 August 2017

Boletis JN

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Transplantation Proceedings

9 August 2017

published in

1 reference

9 August 2017

volume

36

1 reference

9 August 2017

issue

2 Suppl

1 reference

9 August 2017

page(s)

163S-166S

1 reference

Cyclosporine and long-term kidney graft survival

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Cyclosporin monitoring: its role in autoimmune indications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Concentration-controlled trials. What does the future hold?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Immunosuppressant drugs--the role of therapeutic drug monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Limited sampling strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Therapeutic strategies for optimal use of novel immunosuppressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

The temporal profile of calcineurin inhibition by cyclosporine in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Pharmacokinetic validation of neoral absorption profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

The impact of cyclosporin formulation on clinical outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Neoral monitoring: limitations of trough level monitoring and the potential role of limited sampling strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Neoral C(2) monitoring in pediatric liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

New concepts in cyclosporine monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Patient management by Neoral C(2) monitoring: an international consensus statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Clinical validation studies of Neoral C(2) monitoring: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Neoral absorption profiling: an evolution in effectiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Neoral C-2 monitoring in cardiac transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Recommendations for the implementation of Neoral C(2) monitoring in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Therapeutic drug monitoring of immunosuppressant drugs in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Impact of cyclosporine 2‐h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti‐thymocyte globulin induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

Blood cyclosporin concentrations and renal allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.040

10.1016/J.TRANSPROCEED.2004.01.040

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference